Abstract Multiple different biologically and clinically relevant genes are often amplified in invasive breast cancer, including HER2, ESR1, CCND1, and MYC. So far, little is known about their role in tumor progression. To investigate their significance for tumor invasion, we compared pure ductal carcinoma in situ (DCIS) and DCIS associated with invasive cancer with regard to the amplification of these genes. Fluorescence in situ hybridization (FISH) was performed on a tissue microarray containing samples from 130 pure DCIS and 159 DCIS associated with invasive breast cancer. Of the latter patients, we analyzed the intraductal and invasive components separately. In addition, lymph node metastases of 23 patients with invasive carcinoma were included. Amplification rates of pure DCIS and DCIS associated with invasive cancer did not differ significantly (pure DCIS vs. DCIS associated with invasive cancer: HER2 22.7 vs. 24.2%, ESR1 19.0 vs. 24.1%, CCND1 10.0 vs. 14.8%, MYC 11.8 vs. 6.5%; P [ 0.05). Furthermore, we observed a high concordance of the amplification status for all genes if in situ and invasive carcinoma of individual patients were compared. This applied also to the corresponding lymph node metastases. Our results indicate no significant differences between the gene amplification status of DCIS and invasive breast cancer concerning HER2, ESR1, CCND1, and MYC. Therefore, our data suggest an early role of all analyzed gene amplifications in breast cancer development but not in the initiation of invasive tumor growth.
Introduction
Gene amplification is an important mechanism for oncogene overexpression in malignant tumors including breast cancer. HER2, EGFR, MYC, CCND1, ESR1, MDM2, AIB1, FGFR1, S6K, TOPO2A, EMS1, FGF3, AKT2, and PIP4K2 are genes for which amplification has been described in previous breast cancer studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Some of them have established clinical significance. For example, HER2 located at 17q21 is amplified in 15-25% of invasive breast carcinomas and codes for a tyrosine kinase receptor protein that is the target protein for the monoclonal antibody trastuzumab [14] [15] [16] . ESR1 on 6q25 codes for estrogen receptor alpha (ER) and is amplified in 0-22% of breast cancers [17] [18] [19] [20] [21] [22] [23] . ER is the target for various endocrine therapies [24] . MYC is amplified in 8-37% of breast cancers [25, 26] . The gene is located at 8q24 and codes for a helix-loop-helix/leucine zipper protein. Several studies have associated MYC amplifications with unfavorable tumor phenotype and poor prognosis in breast cancer [27] [28] [29] [30] [31] [32] [33] . CCND1 on 11q13 codes for cyclin D1 protein, which controls cell cycle progression during G1-phase. CCND1 has been found amplified in 10-27% of invasive breast carcinomas [34, 35] . Several studies have suggested that CCND1 amplification may be linked with good prognosis and resistance to hormonal therapy [34, 36] .
However, the role of amplification of these genes in the progression from DCIS to invasive breast cancer is unclear. MYC amplification has been described to be absent in the in situ component of 5 MYC-amplified invasive breast cancers in a FISH study [37] . The authors concluded that MYC amplification has a major role in the transition to invasive tumor growth. However, Watson et al. [38] did not find discrepancies between the invasive and in situ components in four amplified tumors in another study using Southern blot and polymerase chain reaction (PCR) analysis.
Concerning HER2 alterations, pure DCIS has been reported to show higher rates of HER2 positivity than invasive breast cancer [39] [40] [41] [42] . Furthermore, several early studies have suggested that HER2 overexpression is more frequent in the in situ than in the invasive component of invasive breast carcinomas [43] [44] [45] .
To clarify the role of amplifications of these important genes in progression from DCIS to invasive cancer, we constructed a tissue microarray including in situ and invasive tumor samples of 159 patients with DCIS associated with invasive cancer as well as samples of 130 pure DCIS. The FISH analysis for HER2, ESR1, CCND1, and MYC demonstrated a remarkably strong concordance between the findings in DCIS and invasive cancer.
Materials and methods

Material
Tissue blocks were available from 289 patients with DCIS. From each of these blocks, one tissue core was taken from the DCIS and placed on our tissue microarray (TMA). 130 of these patients had pure DCIS without invasive cancer. In the remaining 159 patients, DCIS was associated with invasive cancer (predominantly invasive ductal carcinomas, see Table 1 ). In 135 of these patients, sufficient invasive tumor material was available for one additional tissue punch that was taken for the TMA. Additional tissue cores were obtained from lymph node metastases of 23 patients that had axillary lymph node metastasis at the time of primary surgery. In summary, this approach resulted in a TMA composed of 130 in situ samples from 130 patients with pure DCIS, 159 in situ samples, and 135 invasive samples from 159 patients with DCIS and associated invasive cancer, rounded by 23 samples from matched lymph node metastases. All tissues were collected from the archive of the Department of Pathology of the University Medical Center Hamburg-Eppendorf. All tumor tissues were reviewed and graded by experienced pathologists (AL, TG) according to internationally accepted grading systems [46, 47] . TMA construction was as described [48] . Briefly, 447 tissue cylinders with a diameter of 0.6 mm were punched from the ''donor'' tissue blocks using a homemade semiautomatic robotic precision instrument and brought into two different recipient paraffin blocks containing 360 and 87 individual samples. 4 lm sections of the resulting multi-tumor TMA blocks were transferred to an adhesive coated slide system (Instrumedics Inc., Hackensack, New Jersey). An overview of an H&E-stained TMA section is shown in Fig. 1a . . Hybridization and posthybridization washes were done according to the 'LSI procedure' (Vysis-Abbott) for HER2, CCND1, and MYC, or according to the manufacturer's recommendations (ESR1). Slides were then counterstained with 125 ng/ml 4 0 ,6-diamino-2-phenylindole in an antifade solution. Copy numbers of gene specific and the corresponding centromere sequences were estimated for each tissue spot as previously described [17, 49] . 
Supplementary data
The presented results in invasive carcinomas were obtained on tumors selected for the presence of DCIS. To permit a more comprehensive comparison between DCIS and invasive carcinoma, we added a comparison of our current data with FISH data from previous studies on a breast cancer TMA [17, 49] that contained a subset of 1,552 invasive ductal carcinomas. These tumors were not selected for the presence of extensive intraductal component in contrast to the invasive carcinomas included in our current TMA. The probes and scoring criteria used in the previous FISH studies were identical except for ESR1. While FISH analysis in the previous study was performed with a digoxigenin-labeled BAC probe (BAC RP11-450E24, RZPD) containing the ESR1 gene [17] , we used a commercially available ESR1 probe in the current investigation.
Statistics
Contingency table analysis and chi-square test (Likelihood) were used to study the relationship between FISH results and other parameters. SAS software [SAS Institute Inc, JMP 5.1 software (Cary, North Carolina, USA)] was used for data analysis. All significance testing was done at the 0.05 level (two-sided).
Results
Technical aspects
The number of interpretable tissue spots varied between the different FISH probes on our DCIS TMA ( Table 1 ). The number of informative samples was 71.6% for HER2, 66.4% for ESR1, 71.8% for CCND1, and 69.8% for MYC. Analysis failures were due to the absence of tissue on the TMA, lack of unequivocal tumor cells in the arrayed sample or by insufficient hybridization (no signal or too high background). Supplementary amplification data for HER2, ESR1, CCND1, and MYC were also available from 63.5 to 75.1% of 1,552 invasive ductal breast cancers, representing results from previous studies [17, 49] .
Gene amplification in DCIS and invasive cancer Amplification rates of pure DCIS and DCIS associated with invasive cancer did not differ significantly (P [ 0.05; Table 2 and Fig. 2) . In pure DCIS as well as in DCIS associated with invasive cancer, HER2 and MYC amplifications were detected predominantly in high grade (G3) lesions. The associations proved to be statistically significant except for MYC in pure DCIS (P = 0.0904).
The results of the invasive carcinomas associated with DCIS and the invasive ductal carcinomas that were not selected for the presence of DCIS did not differ significantly regarding HER2 and ESR1 (P [ 0.05, Table 2 and Fig. 2 ). But MYC amplification was significantly more frequent in tumors with extensive DCIS (11.7 vs. 5.6%; P = 0.034) in contrast to CCND1 amplification, that was less frequently observed in this group compared to the other (12.6 vs. 21.3%; P = 0.022). The amplification rates of all analysed genes showed significant correlation with histological grade in the previously analyzed invasive ductal carcinomas that were not selected for the presence of DCIS (P \ 0,05; [17, 49] . While the frequency of amplifications increased with grade for HER2, CCND1 and MYC, it decreased for ESR 1. These correlations were also observed for HER2 and MYC but not for ESR1 and CCND1 in the group of invasive carcinomas adjacent of DCIS that were analysed in this study.
DCIS associated with invasive cancer: comparison of in situ and invasive component A high concordance of amplification status was observed for all genes if in situ and invasive areas were compared from individual patients (Fig. 3) . The highest concordance rates were detected for CCND1 (97.3%) and MYC (94.4%). Gene amplifications were detected in the in situ but not in the invasive component of four cases concerning HER2 as well as MYC and six cases regarding ESR1. In contrast, gene amplifications of the invasive but not the corresponding DCIS were observed in four cases concerning ESR1, and two cases regarding CCND1. Reanalysis of all discrepant cases confirmed the initial findings. In one of the four discrepant cases concerning HER2 amplification, the review verified HER2 gene amplification in the DCIS and revealed a borderline HER2 FISH result in the invasive component. In situ tumor cells showed three chromosome 17 and 15 HER2 signals on average (ratio: 5) while a mean number of two centromere and 3.5 HER2 signals where counted in the invasive tumor cells (ratio: 1.75).
Gene amplifications in corresponding nodal metastases: comparison with in situ and invasive component Analyzable tumor tissue from in situ, invasive and lymph node metastasis was available in 12 patients. Although some variations occurred, results showed generally a relatively high concordance rate between the different stages Table 2 Gene amplification frequencies in DCIS and invasive cancer [17, 49] Gene Pure DCIS
DCIS associated with invasive cancer
Invasive breast cancer [17, 49] In situ component * Number of tumors that were successfully analyzed of progression. Concordance rates for HER2, ESR1, CCND1, and MYC were 100, 75, 100, and 81.8%, respectively. Deviations in the amplification status were observed only in rare cases and did not occur regarding HER2 and CCND1 (Fig. 4) .
Discussion
Ductal carcinoma in situ (DCIS) is generally considered as a precursor lesion of invasive ductal breast cancer. Up to 80% of invasive ductal breast carcinomas show at least small foci of DCIS [47] . About 5 to 20% of breast tumors present as pure DCIS without any detectable invasive tumor area at the time of diagnosis [47] . It is estimated that 14 to 50% of DCIS lesions will progress to invasive breast cancer if left untreated [50] . Therefore, pure DCIS is of particular biological interest as its comparison with invasive breast cancer should enable the identification of molecular features driving tumor invasion. Factors needed for invasive tumor growth are likely to be absent in pure DCIS while ''invasion factors'' should be found in all invasive cancers and at least some of the DCIS with transition into invasive cancer. Our series of DCIS contains a representative number of pure DCIS (n = 130) and DCIS associated with invasive breast cancer (n = 159). Similar amplification frequencies found in pure DCIS, DCIS associated with invasive breast cancer and invasive breast cancer for HER2, ESR1, CCND1, and MYC strongly argue against a role of these genes for DCIS progression. To the best of our knowledge, we present the largest study published so far.
Especially the high concordance of the amplification status between invasive cancer and associated in situ component found in this study provides a substantial argument against a role of amplification of the analyzed genes for DCIS progression. Only a few small studies have previously compared gene amplification other than HER2 between DCIS and associated invasive cancer. These have found conflicting data with respect to MYC. RobanusMaandag and co-workers described absence of MYC amplification in DCIS from five patients with adjacent MYC amplified ductal invasive cancer and concluded that MYC amplification may drive transition from DCIS to invasive cancer [37] . But these results were not confirmed by others who found high concordance rates between in situ and invasive tumor components in their small series [38, 51] . Our result of a concordant MYC amplification in 94.3% of the cases virtually rules out a role of MYC amplification for DCIS progression. In this study, HER2 status was concordant in 94.6% of the cases when we analyzed HER2 amplification in the in situ and invasive components of the individual tumors concurrently. A number of early immunohistochemical studies have reported that HER2 overexpression is more frequently observed in the intraductal component of invasive ductal cancers [43] [44] [45] . Since then these results have been widely accepted by the scientific community. For example, the guidelines of the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) on HER2 testing in breast cancer specifically mention the need to avoid unwanted analysis of HER2 positive DCIS included in an otherwise HER2 negative invasive carcinoma [16] . Our study, however, confirms the data of other investigators who analyzed HER2 status by FISH and did not find significant differences between in situ and invasive tumor components [42, 52] . It seems possible that the inherent IHC problems and the absence of interpretation guidelines might have contributed to the discrepant results of the early IHC studies [43] [44] [45] . Somewhat surprising is the relatively low HER2 amplification rate of 22.7% in pure DCIS in this study. The amplification and overexpression of HER2 has been reported in up to 50% of pure DCIS cases [39, 40, 52] . Since HER2 amplification and overexpression is significantly correlated to grade, the relatively high number of non-high grade DCIS analyzed in our study might have contributed to the difference.
A close relationship between DCIS and adjacent invasive breast cancer is also supported by results from other studies showing matching molecular features in DCIS and adjacent invasive cancers. For example, Done et al. found identical p53 mutations in eight DCIS and their corresponding invasive breast cancer [53] . Van der Groep et al. showed similar expression rates of different markers (ER, PR, HER2, CK5/6, CK14, EGFR, and Ki67) in 22 DCIS and their invasive counterparts from patients carrying BRCA1 and BRCA 2 mutations [54] . The expression of COX-2 in invasive breast cancer and associated in situ components was significantly correlated in the investigation of Half et al. [55] . Three PITX2 methylation positive invasive ductal carcinoma examined for methylation markers by Dietrich et al. showed highly methylated PITX2 and RASSF1A in both their invasive and their intraductal components [56] .
Discrepancies concerning the amplification status between DCIS and associated invasive cancer were rare in this study.
Gene amplifications in only six cases were restricted to the invasive component and not accompanied by similar alterations in their individual DCIS precursors (ESR1: n = 4, CCND1: n = 2,). These exceptional cases suggest that ''late amplification development'' may occur in far less than 10% of patients with transition from DCIS to invasive ductal cancer.
Amplification in DCIS but not in adjacent invasive cancers was found for HER2 (n = 4), ESR1 (n = 6) and MYC (n = 4). That tumor cells loose gene amplification at the transition from intraductal to invasive growth in vivo is hardly conceivable. So far, loss of gene amplification has exclusively been described in cell line experiments as a consequence of specific therapeutic manipulations [57] . Hydroxyurea treatment induced reduction of extrachromosomal amplification of MYC in cell lines of four different tissues. However, the mechanisms of loosing gene copy number are not completely clarified by now.
Another potential explanation for the discrepancies is genetic heterogeneity within DCIS. Accordingly, nonamplified invasive cancer would develop on the basis of non-amplified DCIS areas that were not sampled in the TMA. Alternatively, one might speculate that the results reflect the Sontag-Axelrod ''parallel'' model of progression of DCIS and invasive ductal carcinoma [58] . In contrast to the traditional linear model of breast carcinogenesis, the ''parallel'' pathway describes DCIS and invasive breast cancer as diverging from a common progenitor cell and progressing through different grades in parallel. This model is provocative because it calls into question the utility of the current strategy of treating DCIS to prevent invasive ductal cancer [50] . But Sontag and Axelrod have found by complex computer simulation and mathematic modeling that the parallel model produced the most robust correspondence with histological grades of DCIS and invasive cancer reported to occur together in heterogeneous tumors [58] . However, for the majority of DCIS, the observed high concordance between invasive carcinoma and associated DCIS as well as the similar relationship between gene amplifications and histological grade in DCIS and invasive cancer supports the linear concept. According to that low grade carcinomas evolve from low grade DCIS, while high grade carcinomas evolve from high grade DCIS [59] .
Moreover, discrepancies between multiple samples from one patient can either represent true genetic heterogeneity or assessment variability. Scoring variations can easily produce discrepant categorization of samples with borderline FISH results. Especially for ESR1, which is typically amplified at low-level, FISH scoring is subject to interobserver variability [60] . It is therefore not surprising, that ESR1 showed the largest number of variations between DCIS and adjacent invasive cancer in this study. We assume that some of the observed intra-individual discrepancies for ESR1 amplifications are technically induced.
Most of the invasive carcinomas included in our DCIS TMA are of ductal type. These tumors represent a highly selected group of carcinomas because all tumors have an extensive in situ component that is large enough to be utilized for TMA manufacturing. To exclude a bias from this selection, we compared the current results with former amplification data from another set of invasive ductal carcinomas that were not selected for the presence of DCIS [17, 49] . The comparison revealed almost identical amplification rates for HER2 and ESR1. In contrast, MYC amplification was significantly more frequent in tumors with extensive DCIS (11.7 vs. 5.6%; P = 0,034), while CCND1 amplification rate was increased in the unselected group of invasive breast carcinomas (21.3 vs. 12.6%; P = 0,022). Prima facie these results suggest a preferred biological role of MYC for invasive breast cancers evolving slowly from DCIS and a relevance of CCND1 for tumors rapidly progressing. But we are currently not aware of any functional MYC or CCND1 data that could support such hypotheses. With regard to clinical data, it is also unlikely that MYC triggers slow tumor progression. MYC amplification has been correlated with aggressive tumor phenotype and poor clinical outcome [27] . Accordingly, MYC amplification was significantly associated with high tumor grade in the presented invasive tumor sets. Since the differences in grade composition between the two groups of invasive tumors were not evident, and the similar associations of gene amplifications with histological grade in both sets argue for a consistent grading performed in both, it seems most likely that the variable size of the sample sets might have contributed to the supposed difference.
However, the observed overall frequencies of gene amplifications of MYC and CCND1 from both cohorts are in good accordance with published ranges [25, 26, 34, 35] .
In summary, our data show almost identical amplification status for HER2, MYC, CCND1, and ESR1 in noninvasive and invasive breast cancer. They demonstrate that these amplifications occur early in breast cancer development and are unrelated to invasive tumor phenotype.
